Oregon is currently home to 1212 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants
NCT06720038
Recruiting
The objective of the study is to evaluate the safety, tolerability, and immunogenicity of 4 injections of VAX-31 (at 3 dose levels) compared to PCV20 in infants at 2, 4, 6, and 12-15 months of age, in addition to receiving routine US concomitant vaccines. Stage 1 of the study will comprise 3 dose ascending cohorts. Stage 2 of the study will enroll the remainder of the sample size.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
04/30/2025
Locations: Cyn3rgy Research, Gresham, Oregon
Conditions: Pneumococcal Vaccines
Register for Updates
AltaValve Pivotal Trial
NCT06465745
Recruiting
This is a prospective, single arm, multicenter, clinical trial designed to evaluate the safety and performance of the AltaValve System for the treatment of mitral regurgitation in a targeted patient population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence
Register for Updates
Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors
NCT06234098
Recruiting
This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of AT-1965 in patients with advanced, refractory or recurrent solid tumors (nonresectable and/or metastatic) including mTNBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: CBCC Global Research Site 002, Portland, Oregon
Conditions: Solid Tumor
Register for Updates
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
NCT06160128
Recruiting
The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to compare demographic and clinical characteristics of Veterans who are treated or do not receive these different therapies. The investigators will also perform similar descriptive epidemiology for other respiratory viruses, including RSV and influenza and other infectious dis... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: VA Portland Health Care System, Portland, OR, Portland, Oregon
Conditions: COVID-19, SARS-CoV-2 Infection, RSV, Influenza
Register for Updates
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
NCT05364086
Recruiting
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Providence Newberg Medical Center, Newberg, Oregon
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
NCT03996265
Recruiting
This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Saint Charles Health System, Bend, Oregon
Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Register for Updates
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science
NCT00950118
Recruiting
The goal of this study is to identify genes that convey susceptibility to congenital diaphragmatic hernia in humans. The identification of such genes, and examination of their structure and function, will enable a delineation of molecular pathogenesis and, ultimately, prevention or treatment of congenital diaphragmatic hernia. There are many different possible modes of inheritance for congenital anomalies, including autosomal dominant, autosomal recessive, and multifactorial. Multi-factorial inh... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/30/2025
Locations: Oregon Health & Science University, Doernbecher Children's Hospital, Portland, Oregon
Conditions: Congenital Diaphragmatic Hernia
Register for Updates
Shift Worker Intervention for Sleep Health
NCT06384742
Recruiting
The aim of this study is to pilot test a comprehensive, personalized, media-augmented telehealth intervention ("SWISH") designed to improve sleep health among shift workers.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/29/2025
Locations: Oregon State University, Corvallis, Oregon
Conditions: Shift Work Type Circadian Rhythm Sleep Disorder, Insomnia, Psychophysiological
Register for Updates
Hearing Aids for Veterans With Functional Hearing Difficulties
NCT06117254
Recruiting
Every year, approximately 100,000 Veterans seek help at VA Audiology clinics for hearing and communication difficulties only to learn that they have normal hearing sensitivity. Unfortunately, there are very few established options to improve hearing and listening for these patients. To address this need, audiologists are increasingly prescribing hearing aids set to provide a small amount of amplification. Patients may benefit from the amplification or from modern hearing aid features such as noi... Read More
Gender:
ALL
Ages:
Between 18 years and 79 years
Trial Updated:
04/29/2025
Locations: VA Portland Health Care System, Portland, OR, Portland, Oregon
Conditions: Auditory Processing Disorder
Register for Updates
Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform
NCT06099665
Recruiting
This multi-center, prospective, cluster-randomized controlled trial will evaluate Tempus Next automated notifications as an intervention to support identification and evaluation of patients possibly indicated for Valve Intervention (VI). This study will evaluate the impact of Tempus Next's automated notifications on: (1) Transcatheter or surgical procedure for AS or MR; and (2) Clinic visit with at least one member of the Multidisciplinary Heart Team (including time to evaluation) for patients w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Aortic Valve Stenosis, Mitral Regurgitation
Register for Updates
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT06056830
Recruiting
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Oregon Urology, Springfield, Oregon
Conditions: Prostate Cancer, Prostatic Neoplasms
Register for Updates
Ferric Citrate and Chronic Kidney Disease in Children
NCT04741646
Recruiting
We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo. Participants will be recruited from 20... Read More
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
04/29/2025
Locations: OHSU, Portland, Oregon
Conditions: Chronic Kidney Diseases
Register for Updates